Arcellx, Inc. ACLX 深 沪
等待开盘 03-26 09:30:00 美东时间
114.54
-0.150
-0.13%
华盛通- 最 高114.70
- 今 开114.58
- 成交量 112.42万股
- 最 低 114.47
- 昨 收 114.69
- 总市值 66.98亿
- 52周最高 114.91
- 市盈率 静 --
- 换手率 1.92%
- 52周最低 47.8601
- 委 比 30.36%
- 总股本 5847.98万
- 历史最高 114.91
- 量 比 0.54
- 振 幅 0.20%
- 历史最低 6.035
- 每 手 1
- 风险率 14.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion Acquisition
Gilead to acquire Ouro Medicines for $1.675 billion, explores Galapagos collaboration, outlines cost-sharing and royalty terms.
03-25 01:58
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
Momentum warning for health care sector stocks: RSI indicator shows overbought assets. Arcellx (ACLX) and Atea Pharma (AVIR) among top-ranked.
03-18 20:59
Top 2 Health Care Stocks That May Crash This Quarter
2 stocks in healthcare sector flashing warning to investors who value momentum. RSI is an indicator that compares stock strength on up and down days.
03-04 21:55
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, March 3, 2026 /PRNewswire/ --The global oncology market is projected to nearly triple from $279.9...
03-03 22:00
财报速睇 | Arcellx, Inc. 2025财年年度营收0.22亿美元，同比下降79.4%；归母净利润亏损2.29亿美元，同比亏损扩大113.3%
华盛资讯2月27日讯，Arcellx, Inc.公布2025财年年度业绩，公司年度营收0.22亿美元，同比下降79.4%，归母净利润亏损2.29亿美元，同比亏损扩大113.3%。
02-27 13:09
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
美股大行评级 | 潜在涨幅243.25%！泰利克斯制药获花旗升目标价至22.5美元，维持"买入"评级
今日重点评级关注：花旗：维持Telix Pharmaceuticals"买入"评级，目标价从22美元升至22.5美元；摩根士丹利：维持Vir Biotechnology"超配"评级，目标价从20美元升至24美元
02-25 11:03
美股牛股 | Arcellx飙涨超77%，拟获吉利德以78亿美元收购；CRML大涨近14%
Arcellx飙涨超77%，拟获吉利德以78亿美元收购；CRML大涨近14%，其稀土项目获突破性进展；FFAI大涨超17%，宣布推进首款EAI机器人交付>>
02-24 18:48
美股大行评级 | 大摩将康宁目标价从103美元升至127美元；潜在涨幅1779.7%！IGC Pharma获Ascendiant Capital升目标价至5美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从4.75美元升至5美元；Brookline Capital：维持C4 Therapeutics"买入"评级，目标价从20美元升至30美元
02-24 10:27
Are ACLX, VRE, UHG, EHAB Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
02-24 06:22
